When On-Target Misses the Mark: Lessons from HIV Immunogens
|
The target of the HIV vaccine is the surface
glycoprotein Env, which initiates viral entry into host cells and is blocked
by neutralizing antibodies. |
New approach to HIV treatment offers hope to reduce daily drug needs
More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the ... View article...